Work

P2.12-03 COVALENT-102: A Phase 1/1b Study of BMF-219, A Menin Inhibitor in Patients with Unresectable, Metastatic NSCLC, PDAC, and CRC

Year: 2023

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.638

Authors: S. Patel, D. Hong, S.A. Cohen, C. Fountzilas, D. Sommerhalder, S. Radhi, A. Benson, K. He, E. Pisick, A. Bessudo, H. Duvivier, T. Tong, B. Munneke, Y. Kosaka, U. Ahmed, A. Cacovean, S. Morris, T. Butler, A. Spira

Institutions: University of California San Diego, The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Roswell Park Comprehensive Cancer Center, Cancer Treatment Centers of America, Northwestern Medicine, The Ohio State University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045243

FWCI:

Cites:

Cited by:

Related to: 10